Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265863 · ClinicalTrials.gov registry record · Phase 2
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00265863 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 1 participants.
The verdict
NCT00265863, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients with malignant ascites.
Interventions
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265863
The ClinicalTrials.gov registry entry for NCT00265863 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mitomycin C is the first listed.
NCT00265863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265863 about?
NCT00265863 is a clinical study titled "Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites". RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyper...
What is the current status of trial NCT00265863?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2004-08. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00265863?
The interventions under investigation include: mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00265863?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.